Hypoxia-inducible factor (HIF) signaling protects the intestinal mucosa from injury induced by Clostridium difficile toxins, according to the results of a study published in Gastroenterology.

Recurrent CDI is an excellent example of alteration of the microbiome, which leads to disease. The use of probiotics has had limited success in treatment of this illness. By contrast, FMT has been ...

Lumen announced today top-line results from the sentinel cohort of its RePreve Clinical Trial evaluating LMN-201 for Clostridioides difficile infection (CDI). C. difficile infection sustained ...

This content is distributed under a Creative Commons CC BY-SA 4.0 license. You may freely reproduce the text, videos and images it contains, provided that you indicate the author’s name and ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

About LMN-201 and Lumen Bio LMN-201 is orally delivered (capsules; no enema or "bowel cleanse" required) and highly scalable, allowing for much broader potential use in routine CDI management.